NHS Begins Phase II/III Trial of mRNA Vaccine for Head and Neck Cancer

More than 100 HPV16-positive patients are being enrolled across 15 hospitals to test whether adding BioNTech’s mRNA vaccine to pembrolizumab improves outcomes.